FIGURE 8.
Model of our working hypothesis of rituximab resistance in diffuse large B‐cell lymphoma cells. OE, overexpressing; PDK4, pyruvate dehydrogenase kinase 4; R‐CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.